zoster vaccine recombinant

Action and Spectrum

Actions and spectrum:

It stimulates the synthesis of endogenously produced antibodies to convey active immunity.

The vaccination is believed to protect against zoster disease by enhancing the immune response specific to VZV.

Drug Interaction

Adverse Reaction

Frequency defined

50-59 years

Pain in muscles(56.9%)

Fatigue(57%)

Headache(50.6%)

Swelling (30.5%)

Gastrointestinal symptoms(24.3%)

Redness (38.7%)

60-69 years

Pain (82.8%)

Fatigue (45.7%)

Headache(39.6%)

Fever(23.9%)

Myalgia(49%)

70-79 years

Pain (69.2%)

Fatigue(36.6%)

Swelling (23%)

Shivering(19.5%)

Fever (14.3%)

Redness(37.7%)

Immunocompromised adults

≥50 years

Pain (74-75%)

Redness (21-28%)

Headache (15-25%)

Gastrointestinal symptoms(18%)

Myalgia (37-43%)

18-49 years

Pain (80-82%)

Headache (23-38%)

Shivering (20-26%)

Swelling (14-17%)

Gastrointestinal symptoms, grade 3 (2.1%)

Fever, grade 3 (0.5%)

Black Box Warning

Black Box Warning

Not listed

Contraindication / Caution

Contraindication/Caution:

Contraindication:

Hypersensitivity

Syncope

Increased chances of Guillian-Barre syndrome

Pregnancy / Lactation

Pregnancy consideration:

USFDA pregnancy category: safety study not established

Lactation: Data unavailable 

Pregnancy category:

Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.

Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.

Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology:

Data unavailable

Pharmacodynamics:

Pharmacokinetics:

Absorption 

Distribution 

Metabolism

Elimination and excretion

Half-life:

Adminstartion

Administration:

Only for intramuscular administration.

The upper arm’s deltoid region is the recommended administration site.

Patient Information Leaflet

Patient information leaflet

Generic Name: Zoster vaccine, recombinant

Why do we use the Zoster vaccine, recombinant?

The Zoster vaccine, recombinant, is used in the treatment of shingles caused by a virus called varicella-zoster.